CS
ABMD

Credit Suisse’s Abiomed Inc ABMD Stock Holding History

Credit Suisse’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,200
Closed -$834K – 4312
2019
Q2 		$834K Buy
+3,200
New +$849K ﹤0.01% 3066

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Credit Suisse's ABMD Position: Q4 2022 in Review

Credit Suisse sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 353,961 shares — an estimated $87M sold.

Credit Suisse first reported a position in ABMD in Q2 2013 and held it in 38 quarters. The position peaked at $289M in Q1 2021. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Credit Suisse reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Credit Suisse sold 353,961 Abiomed Inc shares in Q4 2022, an estimated $87M.
  • Credit Suisse first reported a position in Abiomed Inc in Q2 2013 and held it in 38 quarters.
  • Credit Suisse's Abiomed Inc position peaked at $289M in Q1 2021.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Credit Suisse's 13F filing for Q4 2022, filed 13 Feb 2023.